Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Lowe

Showing results (741-750 of 755) with videos related to

Pageof 76
Sort By:
JCI Insight|August 28, 2020
Contribution of plasma cells and B cells to hidradenitis suppurativa pathogenesisJohann E Gudjonsson, Lam C Tsoi, Feiyang Ma, et al.
The Cleft Palate-Craniofacial Journal : Official Publication of the American Cleft Palate-Craniofacial Association|January 22, 2020
NAM Therapy-Evidence-Based ResultsElçin Esenlik, Travis Gibson, Serena Kassam, et al.
The Lancet. Infectious Diseases|September 12, 2024
Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trialVictoria Harris, Jane Holmes, Oghenekome Gbinigie-Thompson, et al.
Nucleic Acids Research|October 30, 2014
RNAcentral: an international database of ncRNA sequences, Anton I Petrov, Simon J E Kay, et al.
The New England Journal of Medicine|April 22, 2026
Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk OutpatientsChristopher C Butler, Andrew D Pinto, Victoria Harris, et al.
Nature Communications|February 23, 2024
Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatientsJoseph F Standing, Laura Buggiotti, Jose Afonso Guerra-Assuncao, et al.
BMJ Open|August 7, 2023
Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community (PANORAMIC): protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe diseaseOghenekome Gbinigie, Emma Ogburn, Julie Allen, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 4, 2000
Genome sequence of Halobacterium species NRC-1W V Ng, S P Kennedy, G G Mahairas, et al.
Journal of Cheminformatics|March 27, 2015
The CHEMDNER corpus of chemicals and drugs and its annotation principlesMartin Krallinger, Obdulia Rabal, Florian Leitner, et al.
Clinical and Experimental Immunology|May 31, 2022
Outcomes following SARS-CoV-2 infection in patients with primary and secondary immunodeficiency in the UKAdrian M Shields, Ariharan Anantharachagan, Gururaj Arumugakani, et al.
Pageof 76

Showing results (741-750 of 755) with videos related to

Sort By:
Pageof 76
JCI Insight|August 28, 2020
Contribution of plasma cells and B cells to hidradenitis suppurativa pathogenesisJohann E Gudjonsson, Lam C Tsoi, Feiyang Ma, et al.
The Cleft Palate-Craniofacial Journal : Official Publication of the American Cleft Palate-Craniofacial Association|January 22, 2020
NAM Therapy-Evidence-Based ResultsElçin Esenlik, Travis Gibson, Serena Kassam, et al.
The Lancet. Infectious Diseases|September 12, 2024
Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trialVictoria Harris, Jane Holmes, Oghenekome Gbinigie-Thompson, et al.
Nucleic Acids Research|October 30, 2014
RNAcentral: an international database of ncRNA sequences, Anton I Petrov, Simon J E Kay, et al.
The New England Journal of Medicine|April 22, 2026
Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk OutpatientsChristopher C Butler, Andrew D Pinto, Victoria Harris, et al.
Nature Communications|February 23, 2024
Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatientsJoseph F Standing, Laura Buggiotti, Jose Afonso Guerra-Assuncao, et al.
BMJ Open|August 7, 2023
Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community (PANORAMIC): protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe diseaseOghenekome Gbinigie, Emma Ogburn, Julie Allen, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 4, 2000
Genome sequence of Halobacterium species NRC-1W V Ng, S P Kennedy, G G Mahairas, et al.
Journal of Cheminformatics|March 27, 2015
The CHEMDNER corpus of chemicals and drugs and its annotation principlesMartin Krallinger, Obdulia Rabal, Florian Leitner, et al.
Clinical and Experimental Immunology|May 31, 2022
Outcomes following SARS-CoV-2 infection in patients with primary and secondary immunodeficiency in the UKAdrian M Shields, Ariharan Anantharachagan, Gururaj Arumugakani, et al.
Pageof 76